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mortality and morbidity in infancy: systematic review of
randomised controlled trials
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ABSTRACT
Objective To evaluate the effect of neonatal vitamin A
supplementation on infant mortality, morbidity and early
adverse effects.
Design Systematic review, meta-analysis, and meta-
regression of randomised controlled trials.
Data sources Electronic databases and hand search of
reviews; abstracts and proceedings of conferences.
Review methods Randomised or quasi-randomised or
cluster randomised, placebo controlled trials evaluating
the effect of prophylactic, neonatal (<1 month)
supplementation with synthetic vitamin A on mortality or
morbidity within infancy (<1 year), and early adverse
effects (≤7 days).
Results The six included trials were from developing
countries.Therewasnoconvincingevidenceofareduced
risk of mortality during infancy (relative risk 0.92, 95%
confidence interval 0.75 to 1.12, P=0.393 random effect;
I
2=54.1%) or of an increase in early adverse effects
includingbulgingfontanelle(1.16,0.81to1.65,P=0.418;
I
2=65.3%). No variable emerged as a significant predictor
of mortality, but data for important risk groups (high
maternal night blindness prevalence and low birth
weights) were restricted. Limited data (from one to four
trials) did not indicate a reduced risk of mortality during
theneonatalperiod(0.90,0.75to1.08,P=0.270;I
2=0%),
cause specific mortality, common morbidities (diarrhoea
and others), and admission to hospital. There was,
however, evidence of an increased risk of acute
respiratory infection and a reduced risk of clinic visits.
ConclusionsThereisnoconvincingevidenceofareduced
risk of mortality and possibly morbidity or of increased
earlyadverseeffectsafterneonatalsupplementationwith
vitamin A. There is thus no justification for initiating such
supplementation as a public health intervention in
developing countries for reducing infant mortality and
morbidity.
INTRODUCTION
Prophylactic vitamin A supplementation for children
aged 1-4 is considered to be an effective intervention
for improving child survival in developing countries.
1
Threeprevioussystematicreviews
2-4haveshownasso-
ciated reductions of 23-30% in childhood mortality.
Similar survival benefits have also been reported in
some trials that included infants aged 6-11 months.
5-7
There is, however, no evidence of a reduction in mor-
tality at 1-6 months.
8-11w1 A recent review concluded
that neonatal vitamin A supplementation is associated
with 20% reduction in mortality in babies under
6 months and included it as a core public health inter-
vention for the Asian region.
12 These findings have
been contested because relevant but negative data
were ignored.
13 To provide updated evidence to
inform policy for an annual birth cohort of over 50
million infants, we conducted a systematic review of
randomised controlled trials to evaluate the effect of
prophylactic neonatal supplementation with synthetic
vitamin A on mortality and morbidity in infancy and
early adverse effects.
METHODS
We evaluated the effect of prophylactic supplementa-
tion with synthetic vitaminA in the neonatalperiod (<
1month),irrespectiveofmaternalantenatalor postna-
talvitaminAsupplementationstatus,onmortalityand
morbidity in infancy (<1 year), and early adverse
effects (within one week after the intervention).
We had planned to carry out eight prespecified sub-
groupanalysesfortheallcausemortalitywithin1year:
 Cumulative vitamin A dose received till the age
of 1 month to examine the possibility of a dose-
response relation through a stratified comparison
of low (≤50000 IU) v high (>50000 IU) doses
 Number of vitamin A doses received to examine
the possibility of a relation to dosing frequency
through a stratified comparison of single v
multiple (≥2) doses
 Maternal postpartum vitamin A supplementation
to examine the possibility of an interactive effect
through a stratified comparison of present (≥30%
received simultaneous maternal postpartum
supplementation) v absent (<30% received
simultaneous maternal postpartum
supplementation)
 Baseline maternal vitamin A status to examine
the possibility of a greater response in deficient
participants through a stratified comparison of
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(low) v ≥5% (high), and mean maternal antenatal
or postpartum serum retinol concentrations of
≥1.1 µmol/l (low maternal deficiency) v <1.1
µmol/l (high maternal deficiency)
 Birth weight of the offspring to examine the
possibility of a greater response in more deficient
low birthweight newborns through a comparison
of mortality estimates among newborns with
birth weight <2500 g v ≥2500 g (normal birth
weight)
 Infant mortality rate in the placebo group to
examine the possibility of a greater response
with higher baseline mortality through a
stratified comparison of lower v upper half
(median) of infant mortality rate in included
trials
 Follow-up age to examine the possibility of a
greater response in the first half of infancy
through a stratified comparison of follow-up age
≤6 months v >6 months and
 Development status of the trial area to examine
the possibility of a greater response in high risk
populations through a stratified comparison of
developing v developed countries.
Thetrialsiteswereclassifiedasdevelopingcountriesif
they were categorised as low or medium in the human
development index.
14
Criteria for inclusion
Types of trials—We included randomised or quasi-ran-
domised or cluster randomised, placebo controlled
trials regardless of publication status and language,
that evaluated the effect of prophylactic supplementa-
tion with synthetic vitamin A initiated in the neonatal
period (<1 month), irrespective of maternal antenatal
or postnatal vitamin A supplementation status, on
mortality or morbidity in infancy (<1 year), or early
adverse effects (within a week after the intervention).
Trials using a factorial design with multiple inter-
vention groups were eligible for inclusion.
Types of participants—Participants were apparently
healthy infants in whom prophylactic, synthetic vita-
min A supplementation was initiated in the neonatal
period (<1 month), irrespective of maternal antenatal
or postnatal vitamin A supplementation status. We
excluded trials conducted on selected subgroups of
infants, such as those who were very low birth weight
(<1500 g), HIV positive, born to HIV positive
mothers, or sick or admitted to hospital, as these have
been examined elsewhere.
1516
Types of intervention—Synthetic oral vitamin A sup-
plementation initiated in the neonatal period (<
1month),irrespectiveofmaternalantenatalor postna-
tal vitamin A supplementation status, was compared
with placebo administered to the infant and either pla-
cebo or no supplementation in the mother. If such a
comparison group was not available for the mother-
infant, the intervention group was compared with the
group in which the infant had received placebo while
the mother had received supplementation identical to
the intervention group. We included trials providing
additional interventions if the only difference between
the treatment arms was synthetic oral vitamin A sup-
plementation. We excluded trials supplementing vita-
min A rich foods or β carotene.
Types of outcome measures
Primary—Weexamined allcause mortalityin the child
at two time points: during infancy, in the period
between initiation of intervention and the last follow-
up within the age of 1 year; and during the neonatal
period between initiation of intervention and the last
follow-up within the age of 1 month.
Secondary—In the period between initiation of the
intervention and the last follow-up within the age of
1 year we measured cause specific mortality because
of diarrhoea, acute respiratory infections, and causes
otherthanthese(asdefinedbytheauthors,irrespective
of ascribing a single or multiple causes of death); mor-
bidities because of diarrhoea, acute respiratory infec-
tion or respiratory difficulty, cough or running nose,
ear infection, fever, and vomiting (as defined by the
authors); and severity of morbidities as assessed by
clinic or hospital visits and admissions to hospital (as
defined by the authors). We also measured early
adverse effects including bulging fontanelle, vomiting,
irritability, diarrhoea, and fever (as defined by the
authors) within one week after the intervention.
Searches
We searched computerised bibliographic medical
databases, including Medline, CENTRAL, Embase,
IBIDS, CINAHL, and HealthSTAR and the clinical
trials website (www.clinicaltrials.gov) up to 5 July
2008 with no language restrictions. The broad search
strategy used for Medline was: (“vitamin A” OR reti-
nol) AND (Clinical Trial[ptyp] OR Meta-Analysis
[ptyp] OR Randomized Controlled Trial[ptyp] OR
Review[ptyp] OR Controlled Clinical Trial[ptyp] OR
Journal Article[ptyp]) AND (infant[MeSH]). We
scanned the title and abstract of the trials identified to
excludethosethatwereobviouslyirrelevant,retrieved
the full text of the remaining trials, and identified rele-
vant articles. We also carried out a lateral search using
the related articles linkin PubMed forthe articles initi-
ally included from the search strategy. We reviewed
the reference lists of identified articles and hand
searched reviews and abstracts and proceedings of
international micronutrient conferences. We con-
tacteddonoragencies,“experts,”andauthorsofrecent
vitamin A supplementation trials to identify any addi-
tional or ongoing trials.
Assessment of quality of methods
We assessed quality of the identified trials by the stan-
dard criteria with respect to allocation concealment,
follow-up and blinding.
17 The scores assigned were as
adequate,unclear,inadequate,andnotusedforrando-
misation; adequate, unclear, inadequate, and not used
for allocation concealment; <3%, 3-9.9%, 10-19.9%,
and ≥20% for attrition (percentage of participants
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blinding, and unclear for blinding. Our prespecified
sensitivity analyses on the basis of trial quality were
allocation concealment (adequate v others), attrition
(<10% v ≥10%), and blinding (double blinding v
others).
Data abstraction
We extracted data in duplicate on a pre-tested ques-
tionnaire and contacted authors for additional infor-
mation, if required. For vitamin A supplementation
we collected information on age, form, route, dose,
and frequency. We also recorded data on various
aspects including the trial site, baseline characteristics
of participants, inclusion and exclusion criteria, co-
interventions, compliance monitoring, intention to
treat analysis, and cluster adjustment.
In factorial trials and in multi-arm designs yielding
two or more intervention groups (different dose or
administration regimens, or maternal supplementa-
tion status) and a single control group, we pooled the
dataintheinterventiongroups,includingthevariation
in the intervention characteristic, and compared these
against the single control group to prevent unit of ana-
lysis error.
18
Statistical analysis
Forcomputingthesummaryrelativerisk,weusedrela-
tive risks and 95% confidence intervals or standard
errors from individual studies. In a hierarchical pat-
tern, we gave preference to the relative risk stated by
authorsand recheckedthe calculations fromthe stated
numbers. If the relative risk was not stated, we calcu-
lated it with the following preference order for the
denominator:statedchildyears,numberswithdefinite
outcomeknowntillcompletionofinterventionperiod,
or number randomised. In trials that did not report
intention to treat analysis but had relevant data avail-
able, we reconstructed intention to treat estimates. For
cluster randomised trials, we used the stated cluster
adjustedrelativeriskand95%confidenceinterval,irre-
spective of the method used. In the absence of this
information,wesoughtrawdatafromauthorstocalcu-
late the design effect. If these were not available, we
intended to recalculate the relative risks for sensitivity
analysis using a design effect inflation of SE
19 by the
pooled estimate based on other cluster randomised
trials. If there were no events (or all events) in both
groupsthetrialprovidednoinformationaboutrelative
probabilityoftheeventandwasautomaticallyomitted
from the meta-analysis.
19
Data entry and initial analysis was performed with
SPSS (version 13.0) software and meta-analysis and
meta-regression with user written programs on Stata
(version 9.2) software. We evaluated the presence of
bias in the extracted data using funnel plots.
20 We
also carried out formal statistical tests for funnel plot
asymmetry—namely, the methods of Begg and Egger
—with the user written “metabias” command in Stata
(version 9.2) software.
2122 Pooled estimates (relative
risks with 95% confidence intervals) of the evaluated
outcome measures were calculated by the generic
inverse variance method by the user written “metan”
command in Stata (version 9.2) software.
2123 The nat-
urallogarithmconvertedvaluesoftheindividualstudy
relative risks and their SEs were used for computing
thepooledestimatesasrecommended.
23Thesepooled
estimates were computed with both fixed effects and
random effects model assumptions and expressed in
an exponential form. This program also computes the
formal tests of heterogeneity—namely, the statistic
CochranQandI
2(variationinpooledestimateattribu-
table to heterogeneity).
24
We carried out sensitivity and subgroup analyses
(specified above) for the primary outcome (all cause
mortality during infancy) by disaggregating results
with the user written “metan” command (“by option”)
in Stata (version 9.2) software.
2123 A separate analysis
wasdoneforthosetrialsprovidingdisaggregatedinfor-
mation for mortality for low birthweight and non-low
birthweightinfants.Wecouldnotcarryoutasubgroup
analysis of baseline mortality in the placebo group
because we could not get a uniform measure across
the included trials. We explored the contribution of
these variables to heterogeneity by meta-regression
using the “metareg” command in Stata (version 9.2)
software with the restricted maximum likelihood
option.
25
RESULTS
Trial flow
We identified 19 potentially eligible references.
w1-w19
We excluded eight references (fig 1).
w2-w9 The 11
remaining references provided data on six trials that
satisfied the inclusion criteria; six trials provided mor-
tality data, three had relevant data on morbidity, and
six provided data on adverse effects.
Study characteristics
The baseline characteristics of the included trials and
the notable general and individual study specific
Potentially relevant references identified
and screened for retrieval (n=72)
Potentially appropriate references to be included (n=19)
References (n=11) satisfying criteria for inclusion of trials (n=6)
Trials with usable information by outcome (n=6):
  Trials reporting mortality data (n=6)
  Trials reporting morbidity data (n=3)
  Trials reporting adverse effects data (n=6)
Obviously irrelevant references excluded (n=53)
References excluded (n=8):
 Trials not providing outcomes of interest (n=1)w2
 Data reported in another publication (n=5)w3-w7
 Components of included trials that examined
    HIV positive participants (n=2)w8 w9
Trials withdrawn by outcome (n=0)
Fig 1 | Trial flow for selection of randomised controlled trials
for inclusion in meta-analysis
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Quantitative data synthesis
Mortality during infancy
The six trials were conducted in developing countries
(four in Asia and two in Africa). Two cluster rando-
mised trials were included with design adjusted
results.
w1 w14All trialswere doubleblindwithadequate
allocation concealment, and loss to follow-up was
below 10% in four trials. Three trials followed up par-
ticipants up to 6 months of age. Two trials gave simul-
taneous maternal postpartum vitamin A
supplementation (≥30% mothers in the intervention
arm). Inall trialsthe cumulativedoseof vitamin Awas
≤50000 IU, given as a single dose in five trials and as
two doses in one trial. Information on prevalence of
maternal night blindness was available in only three
trials; of these one recorded a prevalence <5%. In the
threetrialsthatprovidedthisinformationmeanmater-
nal serum retinol concentration in the placebo group
was ≥1.1 µmol/l. Three trials presented results sepa-
rately for low birthweight and non-low birthweight
infants.
The funnel plot was symmetrical, suggesting the
absence of publication bias, which we confirmed
using Egger’s (weighted regression) method (P=0.931
for bias) and Begg’s (rank correlation) method (conti-
nuity corrected P=1.0). There was no convincing evi-
denceofareducedriskofmortalityduringinfancy;the
pooled relative risk was 0.92 (95% confidence interval
0.75 to 1.12, P=0.393; I
2=54.1%, P=0.053) by random
effects model (table 1 and fig 2). Prespecified sensitiv-
ity, subgroup, and meta-regression analyses did not
identifyaconsistentlysignificantpredictorofmortality
response (tables 1 and 2). Stratified analysis of limited
data (three trials), however, suggested a greater
responsewith≥5%prevalenceofmaternalnightblind-
ness.
Mortality during neonatal period
We pooled data from three trials, two from Asia
w12 w14
andonefromAfrica.
w11DatafromtheAfricantrialper-
tainedtothefirstsevendaysoflifeonly.Inthefactorial
design study, mothers in placebo group received sup-
plementation (synthetic vitamin A or β carotene) iden-
tical to the intervention group.
w14 There was no
convincingevidenceofareducedriskofmortalitydur-
ing the neonatal period; pooled relative risk for mor-
tality was 0.90 (0.75 to 1.08, P=0.270; I
2=0%, P=0.834)
by random and fixed effects models.
Cause specific mortality
We pooled data ascertained by verbal autopsy from
four trials,
w11 w12 w15 w17 two each from Africa and Asia.
Therewas no convincing evidence of a reduced risk of
mortality from respiratory, diarrhoeal, or other causes
by random effects model (table 3).
Morbidities and their severity
We pooled data from three trials, two from Asia
w12 w18
and one from Africa.
w16 All these trials were double
blind with adequate allocation concealment and
<10% loss to follow-up in two.
w16 w18Two trials used a
singleinterventiondose,
w12 w16andintwothefollow-up
age was >6 months.
w12 w16 There was no evidence of a
reduced risk of diarrhoea, cough or running nose, ear
infection, fever, or vomiting (table 3). There was an
increased risk of acute respiratory infection or respira-
tory difficulty (1.11, 1.02, 1.21; P=0.015; I
2=0, two
trials). There was a reduced risk of clinic visits (0.81,
0.72, 0.91; P=0.001; I
2=0, two trials) and no evidence
of a reduced risk of admission to hospital (0.75, 0.26,
2.16; P=0.593; one trial).
Early adverse effects
Wepooleddatafromsixtrials(fourfromAsia
w10 w14 w18
w19andtwofromAfrica
w13 w16);onetrialdidnotrecord
any episode of bulging fontanelle
w17 and one did not
record any irritability
w19 in either group. Only two
trials were cluster randomised, but their relative risks
foradverseeffectswereunadjustedfordesigneffect.
w14
w19 In two trials mothers were given simultaneous
maternal postpartum vitamin A supplementation.
w13
w14 In all trials infants received ≤50000 IU vitamin A.
In two trials physicians recorded bulging of fontan-
elle.
w10 w16 In one trial about two thirds of the mothers
of infants in the placebo group received either syn-
theticvitaminAorβcarotene.
w14Therewasnoconvin-
cing evidence of an increased risk of bulging
fontanelle, vomiting, irritability, diarrhoea, or fever
(table 3).
DISCUSSION
We found no convincing evidence of a reduced risk
of all cause mortality during infancy or of an
increased risk of early adverse effects, including
Random effects model
  West (0-1 mo) 1995
  Humphrey 1996
  Rahmathullah 2003
  Malaba 2005
  Benn 2008
  Klemm 2008
Overall (I2=54.1%, P=0.053)
1.07 (0.66 to 1.73)
0.36 (0.15 to 0.84)
0.78 (0.63 to 0.96)
1.24 (0.85 to 1.79)
1.07 (0.79 to 1.44)
0.88 (0.71 to 1.10)
0.92 (0.75 to 1.12)
11.48
4.77
24.70
15.61
19.23
24.21
100.00
0.1 0.2 1 0.5 2
Favours
treatment
Favours
control
Risk ratio
(95% CI)
Risk ratio
(95% CI)
Weight
(%)
Fixed effects model
  West (0-1 mo) 1995
  Humphrey 1996
  Rahmathullah 2003
  Malaba 2005
  Benn 2008
  Klemm 2008
Overall (I2=54.1%, P=0.053)
1.07 (0.66 to 1.73)
0.36 (0.15 to 0.84)
0.78 (0.63 to 0.96)
1.24 (0.85 to 1.79)
1.07 (0.79 to 1.44)
0.88 (0.71 to 1.10)
0.90 (0.80 to 1.02)
6.44
2.06
33.33
10.71
16.40
31.05
100.00
Fig 2 | Forest plots for relative risk of mortality during infancy
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withsyntheticvitaminA.Limiteddatadidnotindicate
a reduced risk of mortality during the neonatal period,
cause specific mortality, morbidities (diarrhoea and
others), and admission to hospital. There was, how-
ever, evidence of an increasedrisk of acute respiratory
infectionandareducedriskofclinicvisits.Novariable
emergedasaconsistentsignificantpredictorofmortal-
ity during infancy but the data for important risk
groups (high prevalence of maternal night blindness
and low birth weight) were quite restricted.
Strengths and limitations of analyses
Inoursystematicreviewweincorporatedrelevantsen-
sitivity and meta-regression analyses. Analysis of six
trials, though admittedly not robust proof, indicated
no formal evidence of publication bias. Cluster and
individual randomised trials were appropriately com-
bined by design effect correction for the primary out-
come. The main conclusion regarding all cause
mortalityremainedstableoveralargespectrumofsen-
sitivity analyses.
Ourstudyhassomespecificlimitations.Allthetrials
we included were conducted in developing countries,
whichlimitsthegeneralisationoffindings.Wehadlim-
iteddata onhighriskgroups(maternal nightblindness
≥5% and low birthweight infants). In the two cluster
randomised trials, adverse effects were unadjusted for
design effect. Duration of follow-up was variable,
which precluded constitution of a uniform measure to
explore baseline mortality as a predictor. Finally, we
used multiple subgroup and meta-regression analyses,
which increased the possibility of false positive results.
Any identified significant predictor should therefore
be considered only as exploratory.
Inclusion and exclusion criteria
Although we intended to exclude non-placebo but
controlled trials to obviate bias caused by the
“Hawthorneeffect,”
26-29wedidnotfindanysuchtrials.
We excluded trials in which participants were HIV
positive or neonates born to HIV positive mothers to
factor for potential effect modification by an immuno-
suppressive condition. In some settings, however, it
would be impossible to distinguish such participants
fromHIV negativeparticipants.Therewasnoconvin-
cing evidence of a reduced risk of mortality during
infancywithdatafromHIVpositivemothersincluded
(0.96, 0.80, 1.15; P=0.674; I
2=65%).
w9 We restricted
age at intervention to the first month of life because
of pragmatic considerations. As the terms newborn
and neonate are used interchangeably to denote age
below 1 month,an alternative time frame of providing
“vitamin A supplements to newborns within the first
few days of life”
30 will create ambiguity. Furthermore,
it would sacrifice data from relevant trial(s), which do
not provide outcomes stratified by exact age within
1 month. The option of including synthetic vitamin A
as a component of the safe delivery kit could not be
examined because the included trials were not specifi-
callydesignedtoadministerthe drugatbirth(immedi-
ately after umbilical cord separation). Nevertheless,
the conclusion regarding mortality during infancy
remained stable when we analysed only dosing within
narrow time windows after birth from the available
data in the five trials irrespective of maternal vitamin
Table 1 |Sensitivity and subgroup analyses for relative risk (RR) of all cause mortality during infancy
Stratification variable* No of trials
RR (95% CI); P value Tests for heterogeneity I2
(%); Q (P value)
P value for heterogeneity in
subgroups Random effects model Fixed effects model
Overall 6 0.92 (0.75 to 1.12); 0.393 0.90 (0.80 to 1.02); 0.090 54.1; 10.90 (0.053) NA
Attrition:
<10% 4 0.89 (0.77 to 1.03); 0.119 0.89 (0.78 to 1.01); 0.065 14.8; 3.52 (0.318)
≥10% 2 0.71 (0.21 to 2.36); 0.576 1.01 (0.72 to 1.42); 0.939 85.4; 6.84 (0.009) 0.465
Follow-up age (months):
≤6 3 0.85 (0.73 to 0.98); 0.024 0.85 (0.73 to 0.98); 0.024 0.0; 1.63 (0.444)
>6 3 0.92 (0.57 to 1.48); 0.715 1.05 (0.83 to 1.31); 0.703 71.0; 6.9 (0.032) 0.123
Maternal postpartum vitamin A supplementation (≥30% mothers):
No 4 0.85 (0.63 to 1.16); 0.305 0.86 (0.73 to 1.01); 0.062 61.2; 7.72 (0.052)
Yes 2 1.01 (0.73 to 1.40); 0.961 0.96 (0.80 to 1.16); 0.676 58.1; 2.39 (0.122) 0.374
No of vitamin A doses received:
Single 5 0.96 (0.76 to 1.23); 0.767 0.97 (0.83 to 1.12); 0.659 51.4; 8.23 (0.083)
Multiple 1 0.78 (0.63 to 0.96); 0.021 0.78 (0.63 to 0.96); 0.021 NA 0.102
Maternal night blindness:
<5% 1 1.24 (0.85 to 1.79); 0.262 1.24 (0.85 to 1.79); 0.262 NA
≥5% 2 0.83 (0.71 to 0.96); 0.014 0.83 (0.71 to 0.96); 0.014 0.0; 0.61 (0.433) 0.049
Birth weight specific†:
Low birth weight 3 0.76 (0.58 to 1.01); 0.056 0.80 (0.69 to 0.93); 0.003 52.7; 4.23 (0.121) 0.380
Other 3 0.78 (0.43 to 1.40); 0.399 0.92 (0.70 to 1.20); 0.514 63.7; 5.50 (0.064)
NA= not applicable.
*Not done for allocation concealment, blinding, trial site, maternal serum retinol and cumulative vitamin A dose received by neonate as all trials were categorised in only one of two strata.
†Restricted to trials depicting results separately for low and non-low birthweight infants. For these data, in Klemm 2008
w14 maternal supplementation with either β carotene or synthetic
vitamin A had also been given in comparison (placebo) group according to randomised allocation in this nested design.
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w11 w12
w14 w15 w17 The pooled estimate (random effects model)
was 0.89 (0.73, 1.09; P=0.256; I
2=56%) for dosing dur-
ing the first 48 hours after birth and 0.88 (0.73, 1.07;
P=0.196;I
2=53%)fordosingduringthefirstsevendays
oflife.Toevaluatecausespecificmortality,wedecided
to pool data from trials reporting a single or multiple
causeofdeath,withtheunderlyingphilosophythatthe
assessed cause had contributed to mortality.
Choice of comparison group
A key issue for data abstraction in multi-arm and fac-
torial design trials is the choice of the comparison
group. For several reasons our control group com-
prised neonates who were given placebo and whose
mothershadreceivedeitherplaceboornosupplemen-
tation. The most satisfactory comparison for policy
should replicate the envisaged intervention, and cur-
rently simultaneous neonatal and maternal supple-
mentation is not under consideration. Also, vitamin
A transferred through breast milk might interact with
neonatal intervention. Postpartum vitamin A supple-
mentation to HIV positive mothers whose infants
remained polymerase chain reaction-negative at
6 weeks
w9 was associated with increased mortality by
age 2 (hazard ratio 1.82, 0.99 to 3.31; P=0.05). Other
trials of antenatal and/or postnatal maternal
supplementation
31w15 also documented an increased
risk of mortality for offspring (relative risks 1.05 and
1.26; P>0.05). Including maternal supplementation
inacontrolgroupcouldthusconceivablyinflatesurvi-
val benefit by increasing mortality in the neonatal pla-
cebo group. Relevant factorial designed trials were
powered only to detect effect sizes pooled across the
various subgroups (maternal supplementation
arms).
w14 w15 Such pooling is usually justified by post
hoc subgroup analyses that show no significant inter-
action between maternal and newborn supplementa-
tion. These analyses, however, are underpowered to
reveal realistic interactions; the power was only 10%
to detect an interaction term (0.88) equivalent to the
observed effect size in the maternal placebo subgroup
in one study.
w14 Trials with 80% power for the overall
effect have only 29% power to detect an interaction
effect of the same magnitude, and even less power for
thesmallerinteractionsthataremorelikelytooccurin
practice.
32 We evaluated the stability of our estimate
(randomeffectsmodel)byalteringthechosencompar-
ison and control groups in the two relevant factorial
designed trials.
w14 w15 On choosing neonatal inter-
vention and control groups irrespective of maternal
supplementation status, the sample size of the control
component increased in these two trials while the
pooled estimate was only marginally lowered (0.89,
0.76 to 1.06; P=0.195; I
2=49%). When we restricted
the analysis to neonatal intervention and control
groups with mothers who were either receiving pla-
cebo or no supplementation, the sample size of the
intervention component diminished in these two trials
while the pooled estimates remained almost similar
(0.90, 0.74, 1.10; P=0.303; I
2=48%). Thus the conclu-
sion regarding mortality during infancy remained
stable irrespective of the chosen comparison and con-
trol groups.
Intention to treat analyses
The Indiantrial stated that “all analyses were based on
intention to treat.”
w17 For a “purist” intention to treat
analysis,
33 however, their estimated mortality risk
should also have included “infants whose mothers
were randomised but who were not enrolled and
received supplementation with vitamin A” (see figure
2oftheirpublication).Whenwereconstructedsuchan
intentionto treatanalysis,the relative riskwas actually
0.87(0.74to1.03;P=0.109;fixedeffectsmodel),which
further strengthens our conclusion in this meta-analy-
sis regarding mortality during infancy (0.94, 0.79 to
1.12; P=0.483; I
2=44.7%; random effects model).
Choice of model
Thereare nocomprehensiverules onwhen touse ran-
domeffectsorfixedeffectsmodelsformeta-analysis.A
fixed effects model assumes that differences between
observed results of trials can be fully accounted for
by sampling variation whereas a random effects
model assumes that outcomes of trials might differ
both because of sampling variation and true diversity
in effects. Both models can be appropriately applied
for pooling but a random effects model is usually pre-
ferred with heterogeneity. We depicted both estimates
for entirety, though we preferred the random effects
model because we observed substantial heterogeneity
(I
2>50%) for mortality during infancy.
No possible at risk groups for evaluating selective
supplementation—namely, ≥5% prevalence of mater-
nal night blindness and low birth weight— emerged as
significant predictors of mortality but the data were
quite limited for a confident interpretation. Appropri-
ately designed trials are therefore required to evaluate
survival benefit in these high risk groups, particularly
the latter, which contributes substantially to infant
mortality. The contradictory findings of an increased
riskofacuterespiratoryinfectionsandadecreasedrisk
of clinic visits are difficult to explain but these pertain
to different datasets of two trials each. As earlier
reviews in older children have also documented an
Table 2 |Meta-regression analyses (univariate analysis*) of all cause infant mortality after
neonatal vitamin A supplementation
Study† characteristic Ratio of RRs‡ (95% CI); I2§ P value
Attrition (≥10% v <10%) 1.00 (0.40 to 2.51); 0.61 0.990
Follow-up age (months) (>6 v ≤6) 1.23 (0.71 to 2.15); 0.53 0.351
Maternal postpartum vitamin A supplementation (≥30%
mothers) (yes v no)
1.18 (0.56 to 2.47); 0.60 0.576
No of vitamin A doses received by infant (multiple v single) 0.80 (0.43 to 1.51); 0.51 0.387
Maternal night blindness (≥5% v <5%) 0.67 (0.05 to 9.01); 0.00 0.300
*Multivariate analysis not performed because no study characteristic was significant predictor of response on
univariate analysis and number of trials was small.
†N=6 except for maternal night blindness (n=3).
‡For binary variables, estimate of effect size is ratio of relative risks for mortality during infancy (treated/control)
in two groups.
§Represents proportion of residual variation caused by heterogeneity.
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vitaminAsupplementation,
3435thisobservationmight
not represent a chance finding.
Comparison with earlier reviews
Our findings are at variance with a recent review,
whichstates“weidentifiedthreereportedtrialsofvita-
min A supplementation in the neonatal period in low
income countries; they showed a 20% reduction in
mortality in babies younger than 6 months (RR=0.80;
95%CI0.66to0.96).”
12Thevariationfromthisearlier
estimate could have several explanations. The authors
did not explicitly state the inclusion and exclusion cri-
teria, timing of supplementation, choice of control
group, and analytical plan to derive their estimate,
36
whichmakesdirectcomparisonimprecise.Theircom-
parisongroupwasprobablyneonatalplaceboirrespec-
tive of maternal supplementation status, which is
different from ours. They also excluded relevant but
negative data from three sources.
w1 w11 w15 In a subse-
quent reappraisal after correspondence questioning
their finding,
13 the authors included data from two of
the earlier excluded sources.
37 This pooled estimate
also did not document any convincing evidence of a
reduction in mortality (relative risk 0.88, 0.73 to 1.06;
P=0.19) after supplementation within three days of
birth, which agrees with the results of our meta-analy-
sis. They selectively evaluated reduction in mortality
up to age 6 months,
37 when three trials had follow-up
extending to age 1 year. Nevertheless, we did not find
any convincing evidence of mortality reduction up to
6 months of age (0.91, 0.76 to 1.09, I
2=43%).
Region specific analyses have suggested evidence of
abenefitinsouthAsiabutnotinAfrica.
37Webasedour
subgroup analyses on underlying biological plausibil-
ity rather than regional considerations. Also, on meta-
regression, region was not a significant predictor of
heterogeneity (P=0.133), although the effect sizes
seemed disparate (1.13, 0.90 to 1.43, I
2=0%, in Africa
and 0.82, 0.66 to 1.02, I
2=45%, in Asia). More trials on
neonatal vitamin A supplementation are therefore
required to determine if there are true regional differ-
ences or some biological characteristics such as high
risk populations explain the findings.
We also found no evidence of a reduction in mortal-
ity after vitamin A supplementation between 1 and
6 monthsof age.
w18-11 It isdifficult to explain the differ-
ences from earlier systematic reviews
2-4 documenting
23-30% reduction in childhood mortality after inter-
vention after the age of 6 months. There was no evi-
dence of benefit in child survival in a trial conducted
recently on one million children in rural India (0.96,
0.88 to 1.05).
38 Trials included in our review were car-
riedoutmorerecently,whenthemagnitudeandsever-
ity of vitamin A deficiency in populations might have
diminished.Causesofmortalityintheneonatalperiod
and in early infancy are different from those after
6 months of age. In high risk settings, a vitamin A
Table 3 |Summary of pooled analyses for all outcomes (relative risks)
Outcomes No of trials
RR (95% CI); P value Heterogeneity I2 (%);
Q (P value) Random effects model Fixed effects model
Mortality during infancy 6 0.92 (0.75 to 1.12); 0.393 0.90 (0.80 to 1.02); 0.090 54.1; 10.90 (0.053)
Mortalityduringneonatalperiod 3 0.90 (0.75 to 1.08); 0.270 0.90 (0.75 to 1.08); 0.270 0; 0.36 (0.834)
Cause specific mortality:
Respiratory 4 1.11 (0.82 to 1.51); 0.484 1.11 (0.82 to 1.51); 0.484 0; 0.34 (0.951)
Diarrhoeal 4 0.98 (0.42 to 2.28); 0.955 0.95 (0.61 to 1.48); 0.809 66; 8.83 (0.032)
Others 4 0.76 (0.56 to 1.02); 0.064 0.78 (0.65 to 0.94); 0.009 48.2; 5.79 (0.122)
Morbidities:
Diarrhoea 3 1.04 (0.99 to 1.09); 0.097 1.04 (0.99 to 1.09); 0.097 0; 0.99 (0.609)
Acute respiratory infection or
respiratory difficulty
2 1.11 (1.02 to 1.21); 0.015 1.11 (1.02 to 1.21); 0.015 0; 0.03 (0.867)
Cough or running nose 3 0.98 (0.85 to 1.13); 0.770 1.03 (0.98 to 1.07); 0.240 68.7; 6.4 (0.041)
Ear infection 1 0.33 (0.03 to 3.38); 0.350 0.33 (0.03 to 3.38); 0.350 Not applicable
Fever 2 0.84 (0.48 to 1.47); 0.548 1.02 (0.99 to 1.05); 0.209 61.8; 2.62 (0.106)
Vomiting 1 1.22 (0.57 to 2.61); 0.608 1.22 (0.57 to 2.61); 0.608 NA
Severe morbidity requiring:
Clinic visits 2 0.81 (0.72 to 0.91); 0.001 0.81 (0.72 to 0.91); 0.001 0; 0.37 (0.542)
Admission to hospital 1 0.75 (0.26 to 2.16); 0.593 0.75 (0.26 to 2.16); 0.593 NA
Early adverse effects:
Bulging fontanelle 5 1.16 (0.81 to 1.65); 0.418 1.06 (0.91 to 1.25); 0.457 65.3; 11.52 (0.021)
Vomiting 4 0.92 (0.77 to 1.09); 0.308 0.91 (0.80 to 1.02); 0.109 23.7; 3.93 (0.269)
Vomiting* 5 0.91 (0.78 to 1.06); 0.214 0.90 (0.80 to 1.02); 0.092 13.9; 4.65 (0.326)
Irritability 3 0.98 (0.86 to 1.11); 0.713 0.98 (0.86 to 1.11); 0.700 1.0; 2.02 (0.364)
Diarrhoea 3 0.92 (0.64 to 1.33); 0.660 0.93 (0.79 to 1.09); 0.358 70.1; 6.69 (0.035)
Fever 4 0.99 (0.79 to 1.24); 0.916 0.99 (0.79 to 1.24); 0.916 0; 1.86 (0.603)
NA=not applicable.
*If all early adverse effects are presumed to be vomiting in Rahmathullah trial
w17(see explanation in appendix 1 on bmj.com).
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6 months, when supplementation is more likely to
have a beneficial effect.
Predictors of heterogeneity
Wewereunabletoidentifyanysignificantpredictorof
substantial heterogeneity for mortality. Additional
variables, not examined by us, might explain the
observed differences. Effects of micronutrient supple-
mentation might be different between boys and girls,
possibly because of variations in prevalence of micro-
nutrient deficiency.
3940 In conformity with the earlier
hypothesis,
w11 a post hoc analysis (random effects
model in four trials
w11 w12 w14 w17) suggested that the
risk of mortality was lower among boys (0.77, 0.59,
1.01)thangirls(0.93,0.73,1.17).Thetwogroups,how-
ever, were not heterogeneous (P=0.400; P=0.439 for
sex on meta-regression). Divergent results might be
explained by differences in vaccination intensity
because vitamin A supplementation might interact
negatively with DPT vaccine in girls.
41 In the Guinea
Bissau trial,
w11 a post hoc analysis suggested that once
children received DPT vaccine, mortality in girls who
had received vitamin A at birth was twice that in girls
who had received placebo at birth.
41 We could not
explore this hypothesis because of lack of relevant
information in the included trials. The possibility of a
strong interaction with season in one trial
w11 could not
beexaminedinothertrials.Noneofthetrialsanalysed
the relation with infant feeding practices.
Implications for policy
Allthereviewedevidencepertainstodevelopingcoun-
tries and is primarily from populations at risk of devel-
oping vitamin A deficiency. Currently, a public health
programme of neonatal synthetic vitamin A
supplementation to reduce infant mortality and mor-
bidity is not justified in these settings because there is
no convincing evidence of survival benefit or a reduc-
tion in morbidity.
Implications for future research
Future research and trials on neonatal vitamin A sup-
plementation should examine effects on mortality and
morbidityinimportantriskgroups(highprevalenceof
maternal night blindness and low birth weight); mor-
tality inmore settingsin Asiaand Africatounderstand
regional differences, if any; morbidities and their
severity; and relation of mortality to potential predic-
tors of response including exact timing of supplemen-
tation, baseline infant mortality rate, maternal vitamin
A status, season, sex, vaccination status, and infant
feeding practices.
Conclusions
Thereisnoconvincingevidenceofareducedriskofall
cause mortality during infancy or of an increased risk
ofearlyadverseeffectsaftersyntheticneonatalvitamin
A supplementation. Limited data do not indicate a
reduced risk of mortality during the neonatal period,
cause specific mortality, or common morbidities.
Thereisthusnojustificationforinitiatingneonatalvita-
minAsupplementationasapublichealthintervention
in developing countries for reducing infant mortality
and morbidity.
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